{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:10:14Z","timestamp":1793682614726,"version":"4.5.1"},"reference-count":26,"publisher":"Japan Neurosurgical Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol. Med. Chir.(Tokyo)"],"published-print":{"date-parts":[[2023,3,15]]},"DOI":"10.2176\/jns-nmc.2022-0179","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T22:11:27Z","timestamp":1674166287000},"page":"111-115","source":"Crossref","is-referenced-by-count":3,"title":["Usefulness of Serum Soluble Interleukin-2 Receptor Levels for Differentiating between PCNSL and SCNSL"],"prefix":"10.2176","volume":"63","author":[{"given":"Yuta","family":"MITOBE","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, Yamagata University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichiro","family":"MATSUDA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, Yamagata University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"SONODA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, Yamagata University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Louis DN, Perry A, Reifenberger G, et al.: The 2016 World Health Organization classification of tumors of the central nervous system: a summary. <i>Acta Neuropathol<\/i> 131: 803-820, 2016","DOI":"10.1007\/s00401-016-1545-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Pfreudschuh M, Tr\u00fcmper L, \u00d6sterborg A, et al.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. <i>Lancet Oncol<\/i> 7: 379-391, 2006","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Coiffier B, Lapage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. <i>N Engl J Med<\/i> 346: 235-242, 2002","DOI":"10.1056\/NEJMoa011795"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Bernstein SH, Unger JM, LeBlanc M, Friedberg J, Miller TP, Fisher R: Natural history of CNS relapse in patients with aggressive non-Hodgkin&apos;s lymphoma: A 20-year follow-up analysis of SWOG 8516-The Southwest Oncology Group. <i>J Clin Oncol<\/i> 27: 114-119, 2009","DOI":"10.1200\/JCO.2008.16.8021"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Korfel A, Schlegel U: Diagnosis and treatment of primary CNS lymphoma. <i>Nat Rev Neurol<\/i> 9: 317-327, 2013","DOI":"10.1038\/nrneurol.2013.83"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Batchelor TT: Primary central nervous system lymphoma: A curable disease. <i>Hematol Oncol<\/i> 37: 15-18, 2019","DOI":"10.1002\/hon.2598"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Mulvenna P, Nankivell M, Barton R, et al.: Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomized trial. <i>Lancet<\/i> 388: 2004-2014, 2016","DOI":"10.1016\/S0140-6736(16)30825-X"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. <i>N Engl J Med<\/i> 352: 987-996, 2005","DOI":"10.1056\/NEJMoa043330"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Watanabe M, Tanaka R, Takeda N, Takeda N: Magnetic resonance imaging and histopathology of cerebral gliomas. <i>Neuroradiology<\/i> 34: 463-469, 1992","DOI":"10.1007\/BF00598951"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Utsuki S, Oka H, Miyajima Y, Kijima C, Yasui Y, Fujii K: Glioblastoma without remarkable contrast enhancement on magnetic resonance imaging. <i>Int J Clin Med<\/i> 3: 439-445, 2012","DOI":"10.4236\/ijcm.2012.36082"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Barajas RF Jr, Cha S: Metastasis in adult brain tumors. <i>Neuroimaging Clin N Am<\/i> 26: 601-620, 2016","DOI":"10.1016\/j.nic.2016.06.008"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Toh CH, Castillo M, Wong AMC, et al.: Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. <i>AJNR Am J Neuroradiol<\/i> 29: 471-475, 2008","DOI":"10.3174\/ajnr.A0872"},{"key":"13","unstructured":"13) Kono K, Inoue Y, Nakayama K, et al.: The role of diffusion-weighted imaging in patients with brain tumors. <i>AJNR Am J Neuroradiol<\/i> 22: 1081-1088, 2001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Haldorsen IS, Espeland A, Larsson EM: Central nervous system lymphoma: Characteristic findings on traditional and advanced imaging. <i>AJNR Am J Neuroradiol<\/i> 32: 984-992, 2011","DOI":"10.3174\/ajnr.A2171"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Senocak E, Oguz KK, Ozgen B, et al.: Parenchymal lymphoma of the brain on initial MR imaging: A comparative study between primary and secondary brain lymphoma. <i>Eur J Radiol<\/i> 79: 288-294, 2011","DOI":"10.1016\/j.ejrad.2010.01.017"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Neska-Matuszewska M, Zimny A, Bladowska J, S\u0105siadek M: Diffusion and perfusion MR patterns of central nervous system lymphomas. <i>Adv Clin Exp Med<\/i> 27: 1099-1108, 2018","DOI":"10.17219\/acem\/73894"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Belykh E, Shaffter KV, Lin C, Byvaltsev VA, Preul MC, Chen L: Blood-brain barrier, blood-brain tumor barrier, and fluorescence-guided neurosurgical oncology: delivering optional labels to brain tumors. <i>Front Oncol<\/i> 10: 739, 2020","DOI":"10.3389\/fonc.2020.00739"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Scott BJ, Douglas VC, Tihan T, Rubenstein JL, Josephson SA: A systematic approach to the diagnosis of suspected central nervous system lymphoma. <i>JAMA Neurol<\/i> 70: 311-319, 2013","DOI":"10.1001\/jamaneurol.2013.606"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kitai R, Sasaki H, Matsuda K, et al.: Measurement and cellular sources of the soluble interleukin-2 receptor in primary central nervous system lymphoma. <i>Brain Tumor Pathol<\/i> 30: 34-39, 2013","DOI":"10.1007\/s10014-012-0093-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Motokura T, Kobayashi Y, Fujita A, et al.: Clinical significance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma. <i>Leuk Lymphoma<\/i> 16: 355-362, 1995","DOI":"10.3109\/10428199509049776"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Murakami J, Arita K, Wada A, et al.: Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions. <i>Mol Clin Oncol<\/i> 11: 474-482, 2019","DOI":"10.3892\/mco.2019.1922"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Nakase K, Tsuji K, Tamaki S, et al.: Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. <i>Cancer Detect Prev<\/i> 29: 256-259, 2005","DOI":"10.1016\/j.cdp.2005.03.001"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Bien E, Balcerska A: Serum soluble interleukin 2 receptor \u03b1 in human cancer of adults and children: a review. <i>Biomarkers<\/i> 13: 1-26, 2008","DOI":"10.1080\/13547500701674063"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kanda Y: Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. <i>Bone Marrow Transplant<\/i> 48: 452-458, 2013","DOI":"10.1038\/bmt.2012.244"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Mohile NA, DeAngelis LM, Abrey LE: The utility of body FDG PET in staging primary central nervous system lymphoma. <i>Neuro Oncol<\/i> 10: 223-228, 2008","DOI":"10.1215\/15228517-2007-061"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Neska-Matuszewska M, Bladowska J, S\u0105siadek M, Zimny A: Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone- Searching for a practical approach. <i>PLoS One<\/i> 13: e0191341, 2018","DOI":"10.1371\/journal.pone.0191341"}],"container-title":["Neurologia medico-chirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/63\/3\/63_2022-0179\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T04:21:37Z","timestamp":1679113297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/63\/3\/63_2022-0179\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2022-0179","relation":{},"ISSN":["0470-8105","1349-8029"],"issn-type":[{"value":"0470-8105","type":"print"},{"value":"1349-8029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"article-number":"2022-0179"}}